Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 858 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Anal Cancer Advances Open Door to Screening and Prevention June 7, 2024 EMA Recommends Extension of Therapeutic Indications for Encorafenib July 3, 2026 For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions June 3, 2021 Experimental mRNA Vaccine Hints at Potential Against Glioblastoma June 11, 2024 Load more HOT NEWS FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July Cómo mi diagnóstico de cáncer a los 17 años cambió mi... FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction...
